Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dextromethorphan quinidine orally disintegrating tablet and application thereof

A technology for dextromethorphan and orally disintegrating tablets, applied in the field of orally disintegrating tablets containing dextromethorphan and quinidine and its preparation, can solve the problems of taste masking of the undisclosed dextromethorphan quinidine composition, and achieve disintegration The effects of short solution time, improved medication experience, and easy-to-accept taste

Active Publication Date: 2022-05-13
BEIJING JITAI PHARM TECH CO LTD +1
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the above two taste-masking related documents do not disclose the taste-masking of the dextromethorphan quinidine composition.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dextromethorphan quinidine orally disintegrating tablet and application thereof
  • Dextromethorphan quinidine orally disintegrating tablet and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Weigh 20mg dextromethorphan hydrobromide, 10mg quinidine sulfate and 2mg colloidal silicon dioxide, mix and sieve, add 32mg mannitol, 16mg xylitol, 40mg microcrystalline cellulose, 10mg crospovidone , 10mg croscarmellose sodium, 4mg sucralose and 4mg peppermint essence, mixed and sieved, mixed evenly again, added 2mg sieved sodium stearyl fumarate, mixed evenly and used dry granulation mechanism grain. Then add 10 mg of sieved crospovidone, 10 mg of sieved croscarmellose sodium and 2 mg of sieved sodium stearyl fumarate, mix well and then compress into tablets to obtain dextromethorphanqui Nitin orally disintegrating tablets.

Embodiment 2

[0052] Weigh 20mg dextromethorphan hydrobromide, 10mg quinidine sulfate and 2mg colloidal silicon dioxide, mix and sieve, add 32mg mannitol, 16mg xylitol, 40mg microcrystalline cellulose, 20mg crospovidone , 4 mg of sucralose and 4 mg of peppermint essence, mixed and sieved, mixed evenly again, adding 2 mg of sieved sodium stearyl fumarate, mixed evenly, and then granulated using a dry granulator. Add 20 mg of sieved crospovidone and 2 mg of sieved sodium stearyl fumarate, mix evenly, and press into tablets to obtain dextromethorphan quinidine orally disintegrating tablets.

Embodiment 3

[0054] Weigh 20mg dextromethorphan hydrobromide, 10mg quinidine sulfate and 2mg colloidal silicon dioxide, mix and sieve, add 32mg mannitol, 16mg xylitol, 40mg microcrystalline cellulose, 20mg crospovidone , 4 mg of aspartame and 4 mg of mint essence, mixed and sieved, mixed again evenly, added 2 mg of sieved sodium stearyl fumarate, mixed evenly, and then granulated using a dry granulator. Add 20 mg of sieved crospovidone and 2 mg of sieved sodium stearyl fumarate, mix evenly, and press into tablets to obtain dextromethorphan quinidine orally disintegrating tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a dextromethorphan quinidine orally disintegrating tablet as well as a preparation method and application of the dextromethorphan quinidine orally disintegrating tablet. The flavoring agent is added into the orally disintegrating tablet, so that the problem that dextromethorphan and quinidine are extremely bitter and numb in taste is solved, the prepared orally disintegrating tablet is easy to disintegrate, the problem that patients suffering from nervous system diseases are difficult to swallow is solved, and meanwhile, the medication experience of the patients is greatly improved. Meanwhile, the dextromethorphan quinidine orally disintegrating tablet provided by the invention is simple in preparation process and suitable for industrial mass production.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an orally disintegrating tablet containing dextromethorphan and quinidine, a preparation method and application thereof. Background technique [0002] Dextromethorphan hydrobromide and quinidine sulfate are a compound drug developed by Avanir pharmaceuticals Inc for the treatment of pseudobulbar affect (PBA), which was first approved by the FDA in October 2010. The drug is the first and only drug for the treatment of PBA, also known as emotional incontinence, mainly secondary to neurological diseases such as Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and stroke. For sudden involuntary crying or laughing. [0003] The taste of dextromethorphan and quinidine is very bad, bitter and numb, and the dosage forms currently on the market are capsules. Patients with neurological diseases are often accompanied by symptoms such as dysphagia and saliv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/20A61K31/485A61K47/26A61K47/36A61K47/38A61K47/32A61K47/02A61K47/12A61K47/18A61P25/00A61P25/28A61K31/4709
CPCA61K31/485A61K31/4709A61K9/0056A61K9/2018A61K9/2013A61K9/2009A61K9/2054A61K9/2027A61K9/2095A61P25/00A61P25/28A61K2300/00
Inventor 戴莉香裘少君殷乐陈强欣李海燕陈红敏赖才达王文首
Owner BEIJING JITAI PHARM TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com